Praxis Precision Medicines is excited to announce that the Essential1 Phase 2b topline data is now available. Results show potential for ulixacaltamide (previously known as PRAX-944) to transform the treatment of essential tremor. To learn more visit https://www.praxisessentialtremor.com. We would like to thank everyone involved in helping us complete our enrollment in this clinical study, including the patients, care partners and advocacy collaborators, including IETF.
Essential1 Study
Research Studies